# Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

> **NCT02280525** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Rituximab
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** NK Cells
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT02280525
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-05
- **Primary completion:** 2019-07-09
- **Final completion:** 2019-07-09
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-06-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02280525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02280525, "Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02280525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*